• Cancel
    Date：2023-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=712

    Hangzhou Wanxiang Cultural Technology Co., Ltd. (" WanXiang Tech " or “Company”), a frontrunner in China's virtual content domain, successfully closed an A2 financing round worth tens of millions of RMB. In this funding round, existing shareholder Porsche Ventures increased its investment, and several strategic investment institutions also participated. CEC Capital acted as the exclusive financial advisor for Wanxiang Tech in this transaction.

  • Cancel
    Date：2023-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=707

    Hangzhou Diagens Biotechnology Co., Ltd. ("Diagens Biotechnology" or "the Company"), a leading reproductive health company in China, recently closed a financing round of RMB 100+ million. This round was led by Grand Flight Investment, with participation f

  • Cancel
    Date：2023-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=710

    Qingdao PHAGEPHARM Biotechnology Co., Ltd. ("PHAGEPHARM" or “Company”), a leading domestic provider of phage-resistant comprehensive solutions, completed a Series B financing round of nearly RMB 100 million. This financing was led by Cenova Capital, with participation from Morningside Ventures and two existing shareholders. CEC Capital served as exclusive financial advisor for this transaction.

  • Cancel
    Date：2023-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=713

    NEXIC Technology, a company specializing in silicon carbide (SiC) power semiconductors, recently secured several hundred million yuan through its Series B and B+ financing rounds. The round was led by Xinchao Innovation Investment Group and JP Xinchao Cap

  • Cancel
    Date：2023-02

    Exclusive Financial Advisor to Concare